Effects of sunitinib targeted chemotherapy on the osseointegration of titanium implants
- 1 April 2018
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 100, 433-440
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Osteonecrosis of the jaw related to sunitinibOral and Maxillofacial Surgery, 2010
- Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancerBreast Cancer Research and Treatment, 2010
- Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic AgentsCancer Investigation, 2009
- Cancer chemotherapy-induced osteoporosis: How common is it among Saudi Arabian cancer survivorsIndian Journal of Cancer, 2009
- Monocytes and dendritic cells in a hypoxic environment: Spotlights on chemotaxis and migrationImmunobiology, 2008
- Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitorBiochemical and Biophysical Research Communications, 2007
- The anti‐angiogenic substance TNP‐470 impairs peri‐implant bone formation: a pilot study in the rabbit metaphysis modelClinical Oral Implants Research, 2007
- A novel mechanism of action of the fumagillin analog, TNP-470, in the B16F10 murine melanoma cell lineAnti-Cancer Drugs, 2005
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996